JP7155470B2 - 免疫原性がん特異的エピトープのためのランク付けシステム - Google Patents

免疫原性がん特異的エピトープのためのランク付けシステム Download PDF

Info

Publication number
JP7155470B2
JP7155470B2 JP2020502531A JP2020502531A JP7155470B2 JP 7155470 B2 JP7155470 B2 JP 7155470B2 JP 2020502531 A JP2020502531 A JP 2020502531A JP 2020502531 A JP2020502531 A JP 2020502531A JP 7155470 B2 JP7155470 B2 JP 7155470B2
Authority
JP
Japan
Prior art keywords
peptide
epitope
mhc class
peptides
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518083A5 (https=
JP2020518083A (ja
Inventor
ヤン、ペイ－ジア
チェン、ジェン－ハオ
チェン、イン－ジャ
チェン、シュ－ジェン
チェン、フア－チエン
Original Assignee
エーシーティー ジェノミックス （アイピー） カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーシーティー ジェノミックス （アイピー） カンパニー リミテッド filed Critical エーシーティー ジェノミックス （アイピー） カンパニー リミテッド
Publication of JP2020518083A publication Critical patent/JP2020518083A/ja
Publication of JP2020518083A5 publication Critical patent/JP2020518083A5/ja
Application granted granted Critical
Publication of JP7155470B2 publication Critical patent/JP7155470B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Data Mining & Analysis (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Artificial Intelligence (AREA)
JP2020502531A 2017-03-31 2018-03-31 免疫原性がん特異的エピトープのためのランク付けシステム Active JP7155470B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762479320P 2017-03-31 2017-03-31
US62/479,320 2017-03-31
PCT/US2018/025597 WO2018183980A2 (en) 2017-03-31 2018-03-31 Ranking system for immunogenic cancer-specific epitopes

Publications (3)

Publication Number Publication Date
JP2020518083A JP2020518083A (ja) 2020-06-18
JP2020518083A5 JP2020518083A5 (https=) 2020-07-30
JP7155470B2 true JP7155470B2 (ja) 2022-10-19

Family

ID=63676910

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502531A Active JP7155470B2 (ja) 2017-03-31 2018-03-31 免疫原性がん特異的エピトープのためのランク付けシステム

Country Status (7)

Country Link
US (1) US11485784B2 (https=)
EP (1) EP3600340A4 (https=)
JP (1) JP7155470B2 (https=)
CN (1) CN110799196B (https=)
SG (1) SG11201907738UA (https=)
TW (1) TWI672503B (https=)
WO (1) WO2018183980A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2729116C2 (ru) * 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
KR102841050B1 (ko) * 2017-04-19 2025-08-01 그릿스톤 바이오, 인코포레이티드 신생항원 동정, 제조, 및 용도
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
CA3115017C (en) * 2018-11-21 2023-10-31 Nec Corporation Method and system of targeting epitopes for neoantigen-based immunotherapy
AU2019404547B2 (en) * 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
WO2020174077A1 (en) 2019-02-28 2020-09-03 Universiteit Antwerpen Method for determining responsiveness to an epitope
US20220208306A1 (en) * 2019-04-30 2022-06-30 Memorial Sloan Kettering Cancer Center System and methods for identification of non-immunogenic epitopes and determining efficacy of epitopes in therapeutic regimens
CN115917654A (zh) * 2020-04-21 2023-04-04 瑞泽恩制药公司 用于分析受体相互作用的方法和系统
JP2024508677A (ja) * 2021-02-05 2024-02-28 アマゾン テクノロジーズ インコーポレイテッド 個別化がんワクチン用ネオアンチゲンのランク付け
US12518851B2 (en) * 2021-09-07 2026-01-06 Nec Corporation Binding peptide generation for MHC class I proteins with deep reinforcement learning for immunotherapy decision making
CN118302816A (zh) * 2021-09-28 2024-07-05 行动基因(智财)有限公司 甲基化生物标记选择装置及方法
WO2025217519A1 (en) * 2024-04-12 2025-10-16 Foundation Medicine, Inc. Clonal neoantigen burden as a biomarker of immunotherapy response

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005301523A (ja) 2004-04-08 2005-10-27 Celestar Lexico-Sciences Inc ワクチン候補部分配列予測装置、ワクチン候補部分配列予測方法、ｍｈｃ結合部分配列予測装置、ｍｈｃ結合部分配列予測方法、プログラムおよび記録媒体
JP2016506907A (ja) 2013-01-15 2016-03-07 メモリアル スローン−ケタリング キャンサー センター 免疫原性ｗｔ−１ペプチドおよびその使用法
WO2016040682A1 (en) 2014-09-10 2016-03-17 Genentech, Inc. Immunogenic mutant peptide screening platform
US20160101170A1 (en) 2013-04-07 2016-04-14 The Broad Institute Inc. Compositions and methods for personalized neoplasia vaccines
WO2016128376A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016172722A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
WO2016174085A1 (en) 2015-04-27 2016-11-03 Cancer Research Technology Limited Method for treating cancer
WO2017011660A1 (en) 2015-07-14 2017-01-19 Personal Genome Diagnostics, Inc. Neoantigen analysis
WO2017042394A1 (en) 2015-09-10 2017-03-16 Cancer Research Technology Limited "immune checkpoint intervention" in cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
CN107704727B (zh) * 2017-11-03 2020-01-31 杭州风起智能科技有限公司 基于肿瘤新抗原特征值的新抗原活性预测和排序方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005301523A (ja) 2004-04-08 2005-10-27 Celestar Lexico-Sciences Inc ワクチン候補部分配列予測装置、ワクチン候補部分配列予測方法、ｍｈｃ結合部分配列予測装置、ｍｈｃ結合部分配列予測方法、プログラムおよび記録媒体
JP2016506907A (ja) 2013-01-15 2016-03-07 メモリアル スローン−ケタリング キャンサー センター 免疫原性ｗｔ−１ペプチドおよびその使用法
US20160101170A1 (en) 2013-04-07 2016-04-14 The Broad Institute Inc. Compositions and methods for personalized neoplasia vaccines
WO2016040682A1 (en) 2014-09-10 2016-03-17 Genentech, Inc. Immunogenic mutant peptide screening platform
WO2016128376A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016172722A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
WO2016174085A1 (en) 2015-04-27 2016-11-03 Cancer Research Technology Limited Method for treating cancer
WO2017011660A1 (en) 2015-07-14 2017-01-19 Personal Genome Diagnostics, Inc. Neoantigen analysis
WO2017042394A1 (en) 2015-09-10 2017-03-16 Cancer Research Technology Limited "immune checkpoint intervention" in cancer

Also Published As

Publication number Publication date
WO2018183980A3 (en) 2018-12-20
EP3600340A2 (en) 2020-02-05
US11485784B2 (en) 2022-11-01
TW201903411A (zh) 2019-01-16
CN110799196B (zh) 2024-02-13
SG11201907738UA (en) 2019-09-27
US20210284738A1 (en) 2021-09-16
EP3600340A4 (en) 2021-01-20
CN110799196A (zh) 2020-02-14
JP2020518083A (ja) 2020-06-18
WO2018183980A2 (en) 2018-10-04
TWI672503B (zh) 2019-09-21

Similar Documents

Publication Publication Date Title
JP7155470B2 (ja) 免疫原性がん特異的エピトープのためのランク付けシステム
US12331359B2 (en) Neoantigens and uses thereof for treating cancer
Zhou et al. Toward in silico identification of tumor neoantigens in immunotherapy
Hundal et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens
Yi et al. caAtlas: An immunopeptidome atlas of human cancer
JP7585195B2 (ja) ネオエピトープを選択する方法
CN110720127A (zh) 新抗原的鉴别、制造及使用
Tang et al. TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification
JP2019501967A (ja) 新生抗原の特定、製造、および使用
CA3217623A1 (en) Compositions and method for optimized peptide vaccines using residue optimization
CN104662171A (zh) 个性化癌症疫苗和过继免疫细胞治疗
US12080382B2 (en) Viral neoepitopes and uses thereof
Kim et al. MHC II immunogenicity shapes the neoepitope landscape in human tumors
CN108700592A (zh) 新表位的迭代发现及其适应性免疫疗法和方法
Morazán-Fernández et al. In silico pipeline to identify tumor-specific antigens for cancer immunotherapy using exome sequencing data
Olsen et al. Bioinformatics for cancer immunotherapy target discovery
Kamali et al. Advancing personalized immunotherapy for melanoma: Integrating immunoinformatics in multi-epitope vaccine development, neoantigen identification via NGS, and immune simulation evaluation
Besser et al. Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides
US12487240B2 (en) Tumor HLA mutation versus matched normal HLA
CN112292464A (zh) 肿瘤功能突变和表位负荷作为免疫治疗反应的改进的预测性生物标志
US20220296642A1 (en) Methods of Making Therapeutic T Lymphocytes
HK40013532B (zh) 致免疫性的癌症特异抗原决定位的排名系统
HK40013532A (en) Ranking system for immunogenic cancer-specific epitopes
RU2826184C2 (ru) Способ отбора неоэпитопов
CA3003304C (en) Viral neoepitopes and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200507

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220912

R150 Certificate of patent or registration of utility model

Ref document number: 7155470

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250